Royal Philips and NYU Langone Health have entered into an eight-year strategic partnership worth up to USD 115 million to improve patient care through further innovation. The new technologies will enable NYU Langone clinicians to collaborate in real time, whether sharing pathology, imaging studies or patient data, to enhance diagnostic confidence and create personalised care plans.
Supported by Philips’ innovation and leadership in health technology, NYU Langone’s industry-leading knowledge of the patient journey and care pathways can help push the boundaries of personalized care. As part of its focus on data access through consolidated technology systems, NYU Langone is committed to unifying patient monitoring systems, simplifying workflows, and creating standards-based interoperability with its electronic medical record (EMR).
NYU Langone Health will deploy Philips’ IntelliSite Pathology solution, enterprise informatics, and AI-enabled diagnostic imaging technologies such as the Philips Lumify Handheld Ultrasound. NYU Langone will also utilize the Philips Patient Information Center iX and the Philips Capsule Medical Device Information Platform (MDIP) to simplify workflows and unlock the power of data.
With the adoption of these technologies, NYU Langone is at the forefront of leveraging a new enterprise monitoring platform and business model to help improve the patient experience, increase staff productivity and reduce the cost of care,” said Julia Strandberg, Chief Business Leader, Connected Care at Philips.
The two organizations have also deepened their existing partnership through the development of new research programs, initially focused on a roadmap for the future of digital pathology, patient monitoring, ultrasound, and MRI.
To view the source version, please click HERE.